Evotec and Ohio State to collaborate on novel cancer therapy

Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ohio-state-to-collaborate-on-novel-cancer-therapy-5259

Weiterlesen

Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration

Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-enter-into-exclusive-negotiations-for-a-major-multi-component-strategic-collaboration-5251

Weiterlesen

Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-as-part-of-its-multi-target-alliance-with-bayer-healthcare-5245

Weiterlesen

Evotec and its partners awarded public grants to develop new drug candidates to treat multiple sclerosis

Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and–its-partners-awarded-public-grants-to-develop-new-drug-candidates-to-treat-multiple-sclerosis-5243

Weiterlesen

Evotec takes legal steps against Andromeda Biotech, Ltd.

Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-takes-legal-steps-against-andromeda-biotech-ltd-5241

Weiterlesen

Evotec and the Jain Foundation expand collaboration: Start of multiple drug screening programmes

Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-expand-collaboration-start-of-multiple-drug-screening-programmes-5239

Weiterlesen